MAVENIR
11.3.2022 08:02:12 CET | Business Wire | Press release
Mavenir, the Network Software Provider building the future of networks with cloud-native software that runs on any cloud and transforms the way the world connects, announced today that together with O2 Telefónica, have demonstrated simplified deployment and change management on Core network elements, leveraging a common Zero Touch Continuous Integration, Continuous Deployment and Continuous Testing (CI/CD/CT) framework in O2 Telefónica’s German network. This will streamline operations in O2 Telefónica OpCos with leaner operations, faster deployments, and simplified operational changes in the network.
This is a significant milestone in the evolution of streamlined operations, moving away from manual deployments and reducing human error. CI/CD provides greater flexibility for customers in day-to-day Operations and is expected to deliver significant benefits in terms of speed and cost of deployment.
Mavenir will work with O2 Telefónica to automate the Network Operations, enabling the transition to the adoption of the virtualized Network Functions. Mavenir’s CI/CD/CT framework will allow for creating customized workflows/processes for fast, agile change management in increased complexity 4G/5G networks. Mavenir’s solution is Opensource-based, interoperable, standardized technology that can be integrated in a “plug and play” manner for any VNF functions.
“5G requires cloud-native and microservices architecture but brings along more operational complexity in the network. CI/CD/CT based zero-touch deployment and change management is our way to be agile and accelerate time to market. This is a key strategy in the path of automation of our networks to achieve leaner and meaner Operations. Mavenir is a trusted and reliable partner for this journey, given the know-how and the experience we have with them in Core & Cloud projects,” said Jochen Bockfeld, Director Common Services, O2 Telefónica Deutschland .
Omar Shahdad, Senior Vice President Global Operations, Mavenir said, “We are honored to have been chosen by O2 Telefónica for this vital part of their network simplification journey. Mavenir is uniquely qualified to provide CI/CD services in the Telco space due to our extensive know-how spanning multiple Telco domains. We are a company that prides itself in its speed, agility, responsiveness, and those are the same required characteristics of a CI/CD program. Mavenir’s solution utilizes high levels of automation and integration that enables our customers to harness the benefits of cloud-native and virtual networks to manage complexity and allow hybrid operations for increased flexibility.”
About Mavenir:
Mavenir is building the future of networks and pioneering advanced technology, focusing on the vision of a single, software-based automated network that runs on any cloud. As the industry's only end-to-end, cloud-native network software provider, Mavenir is focused on transforming the way the world connects, accelerating software network transformation for 250+ Communications Service Providers and Enterprises in over 120 countries, which serve more than 50% of the world’s subscribers. www.mavenir.com
About O2 Telefónica:
O2 Telefónica Deutschland offers telecommunications services for consumers and business customers as well as innovative digital products and services in the area of the Internet of Things and data analytics. The company is one of the leading integrated telecommunications providers in Germany. In mobile communications alone, O2 Telefónica serves more around 46 million mobile lines (incl. M2M - as of 31.12.2021). No network operator connects more people in this country. Under its core brand O2 and various secondary and partner brands, the company sells postpaid and prepaid mobile communications products with innovative mobile data services. The basis for this is the mobile communications network based on a highly resilient GSM, UMTS and LTE infrastructure. At the same time, the company is building a powerful and energy-efficient 5G network. O2 Telefónica also provides telephony and high-speed Internet products based on various technologies in the fixed-network area. Telefónica Deutschland Holding AG has been listed in the Prime Standard segment of the Frankfurt Stock Exchange (TecDAX) since 2012. In the 2021 financial year, the company generated revenue of EUR 7,8 billion with around 7.400 employees. The company is majority-owned by the Spanish telecommunications group Telefónica S.A., headquartered in Madrid. With business activities in 14 countries and a customer base of around 369 million lines, the Group is one of the world's largest telecommunications providers.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220310005203/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release
The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom